Dupilumab Therapy of Prurigo Nodularis: A Single-Center, Real-Life Observational Study

Table 1

Basic information of patients with prurigo nodularis.

Variables	Value n (%)
Sex
Male	22 (76%)
Female	7 (24%)
Age	56.55 ± 3.23
Disease duration	4.87 ± 0.94
Comorbidities
Hypertension	4 (13.79%)
Diabetes	2 (6.90%)
Coronary heart disease	1 (3.45%)
Allergic rhinitis	3 (10.34%)
Eczema	11 (37.93%)
Depression	3 (10.34%)
Anxiety	5 (17.24%)
Sleep disorders	15 (51.72%)
HIV	1 (3.45%)
Family history
Allergic diseases	2 (6.90%)
Eczema	1 (3.45%)
Laboratory examination
Elevated eosinophil count	7 (24.14%)
Elevated Ig E levels	22 (20.69%)
Previous treatment
Antihistamine treatment	29 (100%)
Topical glucocorticoids	29 (100%)
Oral and/or intramuscular injection glucocorticoids	19 (65.52%)
Oral thalidomide	6 (20.69%)
Microneedle therapy	4 (13.79%)